KPC-9, a Novel Carbapenemase from Clinical Specimens in Israel | Zendy

Carlos HidalgoGrass | Zendy; Gabriela Warburg | Zendy; Violeta Temper | Zendy; Shmuel Benenson | Zendy; Allon E. Moses | Zendy; Colin Block | Zendy; Jacob Strahilevitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

KPC-9, a Novel Carbapenemase from Clinical Specimens in Israel

Author(s) -

Carlos HidalgoGrass,

Gabriela Warburg,

Violeta Temper,

Shmuel Benenson,

Allon E. Moses,

Colin Block,

Jacob Strahilevitz

Publication year - 2012

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01156-12

Subject(s) - klebsiella pneumoniae , clone (java method) , microbiology and biotechnology , ceftazidime , escherichia coli , plasmid , drug resistance , virology , enterobacteriaceae , biology , bacteria , gene , genetics , pseudomonas aeruginosa

Abla KPC-9 carbapenemase variant was discovered in isolates ofKlebsiella pneumoniae andEscherichia coli from a single patient. It differed frombla KPC-3 by one amino acid substitution (Val239Ala). TheK. pneumoniae isolate was typed as ST258, as was the epidemic Israeli KPC-3 clone.bla KPC-9 was found on a plasmid indistinguishable from pKpQIL that carriesbla KPC-3 in the epidemic clone. Compared to KPC-3, KPC-9 conferred less resistance to carbapenems and higher resistance to ceftazidime.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research